Stockscreener 앱 받기
2.70
3.91%
-0.11
시간 외 거래:
2.68
-0.02
-0.74%
전일 마감가:
$2.81
열려 있는:
$2.8
하루 거래량:
972.75K
Relative Volume:
0.64
시가총액:
$164.80M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-3.60
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
-2.17%
1개월 성능:
+42.86%
6개월 성능:
-48.77%
1년 성능:
-35.10%
1일 변동 폭
$2.665
$2.82
1주일 범위
$2.38
$2.89
52주 변동 폭
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
2.70 | 164.80M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus
Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - Sete News
Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical - openPR.com
Investing in Aldeyra Therapeutics Inc (ALDX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, In - GuruFocus
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics Inc (ALDX): Why Is Stock So Good? - Marketing Sentinel
Raymond James Financial Inc. Makes New $3.63 Million Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - American Banking and Market News
ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
Wells Fargo & Company MN Acquires 7,348 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Geode Capital Management LLC Grows Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Open Lending Corp. - GlobeNewswire Inc.
Aldeyra Therapeutics Inc (ALDX) Stock: A Year of Declines and Increases - investchronicle.com
Volatility Of Aldeyra Therapeutics Inc (ALDX) Reaches 9.20%: Make Sure To Keep Your Seat Tight! - Stocksregister
ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - GlobeNewswire
Analytical Lens: Exploring Aldeyra Therapeutics Inc (ALDX)’s Financial Story Through Ratios - DWinneX
Aldeyra Therapeutics Inc (ALDX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Latest Insider moments: PERCEPTIVE ADVISORS LLC, Aldeyra Therapeutics Inc [ALDX] 10% Owner sold 3,400,000 shares – Knox Daily - knoxdaily.com
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha
ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit - GlobeNewswire
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors - citybiz
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors | ALDX Stock News - GuruFocus
30-Year Biotech Leader Chip Clark Strengthens Aldeyra Board: Strategic Move for Pipeline Advancement - Stock Titan
Research Analysts Set Expectations for ALDX Q1 Earnings - Defense World
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):